Skip to main content
Top
Published in: BMC Medicine 1/2022

01-12-2022 | Breast Cancer | Research article

Circulating inflammatory biomarkers, adipokines and breast cancer risk—a case-control study nested within the EPIC cohort

Authors: Manon Cairat, Sabina Rinaldi, Anne-Sophie Navionis, Isabelle Romieu, Carine Biessy, Vivian Viallon, Anja Olsen, Anne Tjønneland, Agnès Fournier, Gianluca Severi, Marina Kvaskoff, Renée T. Fortner, Rudolf Kaaks, Krasimira Aleksandrova, Matthias B. Schulze, Giovanna Masala, Rosario Tumino, Sabina Sieri, Chiara Grasso, Amalia Mattiello, Inger T. Gram, Karina Standahl Olsen, Antonio Agudo, Pilar Amiano Etxezarreta, Maria-Jose Sánchez, Carmen Santiuste, Aurelio Barricarte, Evelyn Monninkhof, Anouk E. Hiensch, David Muller, Melissa A. Merritt, Ruth C. Travis, Elisabete Weiderpass, Marc J. Gunter, Laure Dossus

Published in: BMC Medicine | Issue 1/2022

Login to get access

Abstract

Background

Inflammation has been hypothesized to play a role in the development and progression of breast cancer and might differently impact breast cancer risk among pre and postmenopausal women. We performed a nested case-control study to examine whether pre-diagnostic circulating concentrations of adiponectin, leptin, c-reactive protein (CRP), tumour necrosis factor-α, interferon-γ and 6 interleukins were associated with breast cancer risk, overall and by menopausal status.

Methods

Pre-diagnostic levels of inflammatory biomarkers were measured in plasma from 1558 case-control pairs from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. We used conditional logistic regression to estimate the odds ratios (ORs) of breast cancer at blood collection, per one standard deviation increase in biomarker concentration.

Results

Cases were diagnosed at a mean age of 61.4 years on average 8.6 years after blood collection. No statistically significant association was observed between inflammatory markers and breast cancer risk overall. In premenopausal women, borderline significant inverse associations were observed for leptin, leptin-to-adiponectin ratio and CRP [OR= 0.89 (0.77–1.03), OR= 0.88 (0.76–1.01) and OR= 0.87 (0.75–1.01), respectively] while positive associations were observed among postmenopausal women [OR= 1.16 (1.05–1.29), OR= 1.11 (1.01–1.23), OR= 1.10 (0.99–1.22), respectively]. Adjustment for BMI strengthened the estimates in premenopausal women [leptin: OR = 0.83 (0.68–1.00), leptin-to-adiponectin ratio: OR = 0.80 (0.66–0.97), CRP: OR = 0.85 (0.72–1.00)] but attenuated the estimates in postmenopausal women [leptin: OR = 1.09 (0.96–1.24), leptin-to-adiponectin ratio: OR = 1.02 (0.89–1.16), CRP: OR = 1.04 (0.92–1.16)].

Conclusions

Associations between CRP, leptin and leptin-to-adiponectin ratio with breast cancer risk may represent the dual effect of obesity by menopausal status although this deserves further investigation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu Rev Immunol. 2012;30:677–706.CrossRef Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu Rev Immunol. 2012;30:677–706.CrossRef
2.
go back to reference DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007;9(4):212.CrossRef DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007;9(4):212.CrossRef
3.
go back to reference Jiang X, Shapiro DJ. The immune system and inflammation in breast cancer. Mol Cell Endocrinol. 2014;382(1):673–82.CrossRef Jiang X, Shapiro DJ. The immune system and inflammation in breast cancer. Mol Cell Endocrinol. 2014;382(1):673–82.CrossRef
4.
go back to reference Lithgow D, Covington C. Chronic inflammation and breast pathology: a theoretical model. Biol Res Nurs. 2005;7(2):118–29.CrossRef Lithgow D, Covington C. Chronic inflammation and breast pathology: a theoretical model. Biol Res Nurs. 2005;7(2):118–29.CrossRef
5.
go back to reference Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.CrossRef Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.CrossRef
6.
go back to reference Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. 2021;320(3):C375–c91.CrossRef Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. 2021;320(3):C375–c91.CrossRef
7.
go back to reference World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Report: Diet, Nutrition, Physical activity an Breast Cancer. 2017. Available at: wcrf.org/breast.cancer-2017. World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Report: Diet, Nutrition, Physical activity an Breast Cancer. 2017. Available at: wcrf.​org/​breast.​cancer-2017.
8.
go back to reference Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer. 2015;15(8):484–98.CrossRef Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer. 2015;15(8):484–98.CrossRef
9.
go back to reference Chan DS, Bandera EV, Greenwood DC, Norat T. Circulating C-Reactive Protein and Breast Cancer Risk-Systematic Literature Review and Meta-analysis of Prospective Cohort Studies. Cancer Epidemiol Biomark Prev. 2015;24(10):1439–49.CrossRef Chan DS, Bandera EV, Greenwood DC, Norat T. Circulating C-Reactive Protein and Breast Cancer Risk-Systematic Literature Review and Meta-analysis of Prospective Cohort Studies. Cancer Epidemiol Biomark Prev. 2015;24(10):1439–49.CrossRef
10.
go back to reference Dossus L, Jimenez-Corona A, Romieu I, Boutron-Ruault MC, Boutten A, Dupre T, et al. C-reactive protein and postmenopausal breast cancer risk: results from the E3N cohort study. Cancer Causes Control. 2014;25(4):533–9.CrossRef Dossus L, Jimenez-Corona A, Romieu I, Boutron-Ruault MC, Boutten A, Dupre T, et al. C-reactive protein and postmenopausal breast cancer risk: results from the E3N cohort study. Cancer Causes Control. 2014;25(4):533–9.CrossRef
11.
go back to reference Ollberding NJ, Kim Y, Shvetsov YB, Wilkens LR, Franke AA, Cooney RV, et al. Prediagnostic leptin, adiponectin, C-reactive protein, and the risk of postmenopausal breast cancer. Cancer Prev Res. 2013;6(3):188–95.CrossRef Ollberding NJ, Kim Y, Shvetsov YB, Wilkens LR, Franke AA, Cooney RV, et al. Prediagnostic leptin, adiponectin, C-reactive protein, and the risk of postmenopausal breast cancer. Cancer Prev Res. 2013;6(3):188–95.CrossRef
12.
go back to reference Zhang SM, Lin J, Cook NR, Lee IM, Manson JE, Buring JE, et al. C-reactive protein and risk of breast cancer. J Natl Cancer Inst. 2007;99(11):890–4.CrossRef Zhang SM, Lin J, Cook NR, Lee IM, Manson JE, Buring JE, et al. C-reactive protein and risk of breast cancer. J Natl Cancer Inst. 2007;99(11):890–4.CrossRef
13.
go back to reference Gunter MJ, Wang T, Cushman M, Xue X, Wassertheil-Smoller S, Strickler HD, Rohan TE, Manson JE, McTiernan A, Kaplan RC, Scherer PE, Chlebowski RT, Snetselaar L, Wang D, Ho GY. Circulating Adipokines and Inflammatory Markers and Postmenopausal Breast Cancer Risk. J Natl Cancer Inst. 2015;107(9):djv169. Gunter MJ, Wang T, Cushman M, Xue X, Wassertheil-Smoller S, Strickler HD, Rohan TE, Manson JE, McTiernan A, Kaplan RC, Scherer PE, Chlebowski RT, Snetselaar L, Wang D, Ho GY. Circulating Adipokines and Inflammatory Markers and Postmenopausal Breast Cancer Risk. J Natl Cancer Inst. 2015;107(9):djv169.
14.
go back to reference Nelson SH, Brasky TM, Patterson RE, Laughlin GA, Kritz-Silverstein D, Edwards BJ, et al. The Association of the C-Reactive Protein Inflammatory Biomarker with Breast Cancer Incidence and Mortality in the Women's Health Initiative. Cancer Epidemiol Biomark Prev. 2017;26(7):1100–6.CrossRef Nelson SH, Brasky TM, Patterson RE, Laughlin GA, Kritz-Silverstein D, Edwards BJ, et al. The Association of the C-Reactive Protein Inflammatory Biomarker with Breast Cancer Incidence and Mortality in the Women's Health Initiative. Cancer Epidemiol Biomark Prev. 2017;26(7):1100–6.CrossRef
15.
go back to reference Gross AL, Newschaffer CJ, Hoffman-Bolton J, Rifai N, Visvanathan K. Adipocytokines, inflammation, and breast cancer risk in postmenopausal women: a prospective study. Cancer Epidemiol Biomark Prev. 2013;22(7):1319–24.CrossRef Gross AL, Newschaffer CJ, Hoffman-Bolton J, Rifai N, Visvanathan K. Adipocytokines, inflammation, and breast cancer risk in postmenopausal women: a prospective study. Cancer Epidemiol Biomark Prev. 2013;22(7):1319–24.CrossRef
16.
go back to reference Harris HR, Tworoger SS, Hankinson SE, Rosner BA, Michels KB. Plasma leptin levels and risk of breast cancer in premenopausal women. Cancer Prev Res. 2011;4(9):1449–56.CrossRef Harris HR, Tworoger SS, Hankinson SE, Rosner BA, Michels KB. Plasma leptin levels and risk of breast cancer in premenopausal women. Cancer Prev Res. 2011;4(9):1449–56.CrossRef
17.
go back to reference Frydenberg H, Thune I, Lofterød T, Mortensen ES, Eggen AE, Risberg T, et al. Pre-diagnostic high-sensitive C-reactive protein and breast cancer risk, recurrence, and survival. Breast Cancer Res Treat. 2016;155(2):345–54.CrossRef Frydenberg H, Thune I, Lofterød T, Mortensen ES, Eggen AE, Risberg T, et al. Pre-diagnostic high-sensitive C-reactive protein and breast cancer risk, recurrence, and survival. Breast Cancer Res Treat. 2016;155(2):345–54.CrossRef
18.
go back to reference Zeleniuch-Jacquotte A, Gu Y, Bruning PF, Bonfrer JM, Koenig KL, Arslan AA, et al. Re: C-reactive protein and risk of breast cancer. J Natl Cancer Inst. 2008;100(6):443–4 author reply 4-5.CrossRef Zeleniuch-Jacquotte A, Gu Y, Bruning PF, Bonfrer JM, Koenig KL, Arslan AA, et al. Re: C-reactive protein and risk of breast cancer. J Natl Cancer Inst. 2008;100(6):443–4 author reply 4-5.CrossRef
19.
go back to reference Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet (London, England). 1996;347(9017):1713–27.CrossRef Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet (London, England). 1996;347(9017):1713–27.CrossRef
20.
go back to reference IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. IARC monographs on the evaluation of carcinogenic risks to humans :combined estrogen−progestogen contraceptives and combined estrogen−progestogen menopausal therapy. A review of human carcinogens. Lyon: International Agency for Research on Cancer; 2007. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. IARC monographs on the evaluation of carcinogenic risks to humans :combined estrogen−progestogen contraceptives and combined estrogen−progestogen menopausal therapy. A review of human carcinogens. Lyon: International Agency for Research on Cancer; 2007.
21.
go back to reference Feigelson HS, Jonas CR, Teras LR, Thun MJ, Calle EE. Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol Biomark Prev. 2004;13(2):220–4.CrossRef Feigelson HS, Jonas CR, Teras LR, Thun MJ, Calle EE. Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol Biomark Prev. 2004;13(2):220–4.CrossRef
22.
go back to reference Agnoli C, Grioni S, Pala V, Allione A, Matullo G, Gaetano CD, et al. Biomarkers of inflammation and breast cancer risk: a case-control study nested in the EPIC-Varese cohort. Sci Rep. 2017;7(1):12708.CrossRef Agnoli C, Grioni S, Pala V, Allione A, Matullo G, Gaetano CD, et al. Biomarkers of inflammation and breast cancer risk: a case-control study nested in the EPIC-Varese cohort. Sci Rep. 2017;7(1):12708.CrossRef
23.
go back to reference Cust AE, Stocks T, Lukanova A, Lundin E, Hallmans G, Kaaks R, et al. The influence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study. Breast Cancer Res Treat. 2009;113(3):567–76.CrossRef Cust AE, Stocks T, Lukanova A, Lundin E, Hallmans G, Kaaks R, et al. The influence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study. Breast Cancer Res Treat. 2009;113(3):567–76.CrossRef
24.
go back to reference Gaudet MM, Falk RT, Gierach GL, Lacey JV Jr, Graubard BI, Dorgan JF, et al. Do adipokines underlie the association between known risk factors and breast cancer among a cohort of United States women? Cancer Epidemiol. 2010;34(5):580–6.CrossRef Gaudet MM, Falk RT, Gierach GL, Lacey JV Jr, Graubard BI, Dorgan JF, et al. Do adipokines underlie the association between known risk factors and breast cancer among a cohort of United States women? Cancer Epidemiol. 2010;34(5):580–6.CrossRef
25.
go back to reference Tworoger SS, Eliassen AH, Kelesidis T, Colditz GA, Willett WC, Mantzoros CS, et al. Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab. 2007;92(4):1510–6.CrossRef Tworoger SS, Eliassen AH, Kelesidis T, Colditz GA, Willett WC, Mantzoros CS, et al. Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab. 2007;92(4):1510–6.CrossRef
26.
go back to reference Macis D, Gandini S, Guerrieri-Gonzaga A, Johansson H, Magni P, Ruscica M, et al. Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer. J Clin Oncol. 2012;30(2):151–7.CrossRef Macis D, Gandini S, Guerrieri-Gonzaga A, Johansson H, Magni P, Ruscica M, et al. Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer. J Clin Oncol. 2012;30(2):151–7.CrossRef
27.
go back to reference Heikkila K, Harris R, Lowe G, Rumley A, Yarnell J, Gallacher J, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control. 2009;20(1):15–26.CrossRef Heikkila K, Harris R, Lowe G, Rumley A, Yarnell J, Gallacher J, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control. 2009;20(1):15–26.CrossRef
28.
go back to reference Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomark Prev. 2005;14(10):2413–8.CrossRef Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomark Prev. 2005;14(10):2413–8.CrossRef
29.
go back to reference Dias JA, Fredrikson GN, Ericson U, Gullberg B, Hedblad B, Engstrom G, et al. Low-Grade Inflammation, Oxidative Stress and Risk of Invasive Post-Menopausal Breast Cancer - A Nested Case-Control Study from the Malmo Diet and Cancer Cohort. PLoS One. 2016;11(7):e0158959.CrossRef Dias JA, Fredrikson GN, Ericson U, Gullberg B, Hedblad B, Engstrom G, et al. Low-Grade Inflammation, Oxidative Stress and Risk of Invasive Post-Menopausal Breast Cancer - A Nested Case-Control Study from the Malmo Diet and Cancer Cohort. PLoS One. 2016;11(7):e0158959.CrossRef
30.
go back to reference Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002;5(6b):1113–24.CrossRef Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002;5(6b):1113–24.CrossRef
31.
go back to reference Spencer EA, Appleby PN, Davey GK, Key TJ. Validity of self-reported height and weight in 4808 EPIC-Oxford participants. Public Health Nutr. 2002;5(4):561–5.CrossRef Spencer EA, Appleby PN, Davey GK, Key TJ. Validity of self-reported height and weight in 4808 EPIC-Oxford participants. Public Health Nutr. 2002;5(4):561–5.CrossRef
32.
go back to reference Wareham NJ, Jakes RW, Rennie KL, Schuit J, Mitchell J, Hennings S, et al. Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Public Health Nutr. 2003;6(4):407–13.CrossRef Wareham NJ, Jakes RW, Rennie KL, Schuit J, Mitchell J, Hennings S, et al. Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Public Health Nutr. 2003;6(4):407–13.CrossRef
33.
go back to reference Tobias DK, Akinkuolie AO, Chandler PD, Lawler PR, Manson JE, Buring JE, et al. Markers of Inflammation and Incident Breast Cancer Risk in the Women's Health Study. Am J Epidemiol. 2018;187(4):705–16.CrossRef Tobias DK, Akinkuolie AO, Chandler PD, Lawler PR, Manson JE, Buring JE, et al. Markers of Inflammation and Incident Breast Cancer Risk in the Women's Health Study. Am J Epidemiol. 2018;187(4):705–16.CrossRef
34.
go back to reference Wang J, Lee IM, Tworoger SS, Buring JE, Ridker PM, Rosner B, et al. Plasma C-reactive protein and risk of breast cancer in two prospective studies and a meta-analysis. Cancer Epidemiol Biomark Prev. 2015;24(8):1199–206.CrossRef Wang J, Lee IM, Tworoger SS, Buring JE, Ridker PM, Rosner B, et al. Plasma C-reactive protein and risk of breast cancer in two prospective studies and a meta-analysis. Cancer Epidemiol Biomark Prev. 2015;24(8):1199–206.CrossRef
35.
go back to reference Touvier M, Fezeu L, Ahluwalia N, Julia C, Charnaux N, Sutton A, et al. Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case-control study. Am J Epidemiol. 2013;177(1):3–13.CrossRef Touvier M, Fezeu L, Ahluwalia N, Julia C, Charnaux N, Sutton A, et al. Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case-control study. Am J Epidemiol. 2013;177(1):3–13.CrossRef
36.
go back to reference Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol. 2009;27(13):2217–24.CrossRef Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol. 2009;27(13):2217–24.CrossRef
37.
go back to reference Brannian JD, Hansen KA. Leptin and ovarian folliculogenesis: implications for ovulation induction and ART outcomes. Semin Reprod Med. 2002;20(2):103–12.CrossRef Brannian JD, Hansen KA. Leptin and ovarian folliculogenesis: implications for ovulation induction and ART outcomes. Semin Reprod Med. 2002;20(2):103–12.CrossRef
38.
go back to reference Falk RT, Brinton LA, Madigan MP, Potischman N, Sturgeon SR, Malone KE, et al. Interrelationships between serum leptin, IGF-1, IGFBP3, C-peptide and prolactin and breast cancer risk in young women. Breast Cancer Res Treat. 2006;98(2):157–65.CrossRef Falk RT, Brinton LA, Madigan MP, Potischman N, Sturgeon SR, Malone KE, et al. Interrelationships between serum leptin, IGF-1, IGFBP3, C-peptide and prolactin and breast cancer risk in young women. Breast Cancer Res Treat. 2006;98(2):157–65.CrossRef
39.
go back to reference Finucane FM, Luan J, Wareham NJ, Sharp SJ, O'Rahilly S, Balkau B, et al. Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia. 2009;52(11):2345–9.CrossRef Finucane FM, Luan J, Wareham NJ, Sharp SJ, O'Rahilly S, Balkau B, et al. Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia. 2009;52(11):2345–9.CrossRef
40.
go back to reference Clendenen TV, Arslan AA, Lokshin AE, Idahl A, Hallmans G, Koenig KL, et al. Temporal reliability of cytokines and growth factors in EDTA plasma. BMC Res Notes. 2010;3:302.CrossRef Clendenen TV, Arslan AA, Lokshin AE, Idahl A, Hallmans G, Koenig KL, et al. Temporal reliability of cytokines and growth factors in EDTA plasma. BMC Res Notes. 2010;3:302.CrossRef
Metadata
Title
Circulating inflammatory biomarkers, adipokines and breast cancer risk—a case-control study nested within the EPIC cohort
Authors
Manon Cairat
Sabina Rinaldi
Anne-Sophie Navionis
Isabelle Romieu
Carine Biessy
Vivian Viallon
Anja Olsen
Anne Tjønneland
Agnès Fournier
Gianluca Severi
Marina Kvaskoff
Renée T. Fortner
Rudolf Kaaks
Krasimira Aleksandrova
Matthias B. Schulze
Giovanna Masala
Rosario Tumino
Sabina Sieri
Chiara Grasso
Amalia Mattiello
Inger T. Gram
Karina Standahl Olsen
Antonio Agudo
Pilar Amiano Etxezarreta
Maria-Jose Sánchez
Carmen Santiuste
Aurelio Barricarte
Evelyn Monninkhof
Anouk E. Hiensch
David Muller
Melissa A. Merritt
Ruth C. Travis
Elisabete Weiderpass
Marc J. Gunter
Laure Dossus
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2022
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-022-02319-y

Other articles of this Issue 1/2022

BMC Medicine 1/2022 Go to the issue